Successful ruxolitinib administration for a patient with steroid‐refractory idiopathic pneumonia syndrome following hematopoietic stem cell transplantation: A case report and literature review

Idiopathic pneumonia syndrome (IPS) is an acute lung complication observed after the early posthematopoietic stem cell transplantation (HSCT) period. Ruxolitinib was effective for a patient with myelodysplastic syndrome who developed severe IPS after second HSCT. No severe adverse effects were obser...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomomasa, Dan, Isoda, Takeshi, Mitsuiki, Noriko, Yamashita, Motoi, Morishita, Aoi, Tomoda, Takahiro, Okano, Tsubasa, Endo, Akifumi, Kamiya, Takahiro, Yanagimachi, Masakatsu, Imai, Kohsuke, Kanegane, Hirokazu, Takagi, Masatoshi, Morio, Tomohiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693824/
https://www.ncbi.nlm.nih.gov/pubmed/34987813
http://dx.doi.org/10.1002/ccr3.5242
Descripción
Sumario:Idiopathic pneumonia syndrome (IPS) is an acute lung complication observed after the early posthematopoietic stem cell transplantation (HSCT) period. Ruxolitinib was effective for a patient with myelodysplastic syndrome who developed severe IPS after second HSCT. No severe adverse effects were observed. Ruxolitinib may be an alternative choice for HSCT‐related IPS.

Ejemplares similares